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Abstract
Here we study the role of nitric oxide in the vaginal infection of Balb/c mice with herpes simplex virus type 2. Inducible nitric oxide
synthase (iNOS) mRNA was detected by RT-PCR in vaginal tissue and inguinal lymph nodes early postinfection. iNOS was also found to
be activated in cells recovered from vaginal washings of infected animals. Animals treated with aminoguanidine (AG), an iNOS inhibitor,
showed a dose-dependent increase in vaginal pathology after viral infection compared to controls. Viral titers in vaginal washings and
vaginas were higher in AG-treated mice. Treated animals presented higher PMN counts in vaginal washings compared to controls.
Histopathology studies revealed a profound inflammatory exudate in vaginal tissue of treated animals. Finally, RT-PCR analysis showed
increased expression of the chemokines MIP-2 and RANTES in vaginal tissue and inguinal lymph nodes of these animals.
© 2003 Elsevier Science (USA). All rights reserved.
Introduction
Herpes simplex viruses (HSV) 1 and 2 are responsible
for a large spectrum of human diseases that include sys-
temic infections in the newborn and immunocompromised
individuals. Localized infections such as stomatitis or in-
fection of the cornea, genital organs, or CNS have been
described in man and different animal models (Stanberry et
al., 1982, Parr et al., 1994). Both innate and acquired im-
mune responses are fundamental components of a success-
ful host response to HSV infection. The humoral immune
response to virus facilitates antibody-dependent cell-medi-
ated cytotoxicity and neutralizes cell-free virions with both
type-specific and cross-reacting antibodies, but HSV can
spread by a cell-to-cell mode, even under high concentra-
tions of antibody and complement. Because the virus
spreads rapidly from a cell to neighboring cells without
being exposed to the fluid phase, the reaction of specific
antibody and complement appears to have little ability to
stop this spread of infection (McDermott et al., 1990).
Clearence of virus from infected tissue is most often T-cell-
mediated and involves both cytokine-mediated effector
mechanisms and direct cytotoxic effects on virus-infected
cells. Control of acute HSV infections can be accomplished
by either CD4 or CD8 T cells depending on variables
such as virus dose, tissue site, or genetic background (Mil-
ligan and Bernstein, 1995; McDermott et al., 1998; Milligan
et al., 1998). Macrophages are primary mediators of innate
host defense mechanisms. The antiviral mechanisms of
these cells seem to be related to increased cytokine produc-
tion as well as to an increased ability of these cells to
destroy the virus. The production of tumor necrosis factor 
(TNF-) and interferons (IFNs) augments the protective
functions of macrophages and may act directly on infected
cells to suppress HSV replication (Taguchi et al., 1980;
Stohlman et al., 1982). These cytokines also have the ability
to induce the expression of inducible nitric oxide synthase
(iNOS), a gene encoding an inducible isoform of NOS that
produces large amounts of nitric oxide (NO). NO is a free
radical gaseous molecule that is a mediator of vital physi-
ologic functions including host defense (Croen, 1993; Ka-
* Corresponding author. CRRWH, University of Pennsylvania, 421
Curie Boulevard, BRB II/III Room 1316, Philadelphia, PA 19104, USA.
E-mail address: fbenencia@hotmail.com (F. Benencia).
1 Member of the Consejo Nacional de Investigaciones Cientificas
(CONICET), Argentina.
R
Available online at www.sciencedirect.com
Virology 309 (2003) 75–84 www.elsevier.com/locate/yviro
0042-6822/03/$ – see front matter © 2003 Elsevier Science (USA). All rights reserved.
doi:10.1016/S0042-6822(02)00057-0
rupiah et al., 1993; Rolph et al., 1996; Amaro et al., 1997;
Lane et al., 1997). Different investigators have reported
antiviral activity of NO against several viruses such as
vaccinia virus, vesicular stomatitis virus, and Japanese en-
cephalitis virus, among others (Bi et al., 1995; Harris et al.,
1995; Lin et al., 1997; Pertile, 1996). The antiviral activity
of NO, at least in vitro, involves a blockade at the stage of
DNA replication but has no effect on early protein synthesis
(MacMicking et al., 1997).
In this work we study the role of NO in the genital
infection with HSV-2 in Balb/c mice.
Results
In vitro inhibition of HSV-2 replication by NO produced
by S-nitroso-N-acetylpenicillamine (SNAP)
To ascertain the susceptibility of HSV-2, strain G,
replication in cell cultures to NO, SNAP was used as an
exogenous NO donor. SNAP, which is the nitrosylated
form of L-acetylpenicillamine, provides NO in culture
medium. As indicated in Fig. 1A, the addition of SNAP
inhibited HSV-2, strain G, replication in a dose-depen-
dent manner as described with other HSV strains (Croen,
1993). The antiviral effects of SNAP appeared to corre-
late with the amounts of NO produced in culture medium
(SNAP concentrations 1000, 250, 50, and 25 M; NO
concentrations 425, 120, 16, and 5.1 M; viral titer
reduction 95.6, 78, 33, and 6%, respectively) (Fig. 1B).
To determine whether the antiviral effect of SNAP was
due merely to the cytotoxic effect of SNAP on HSV-
infected cells, an 3-(4,5-dimethylthiazol-2-yl)-2,5-diphe-
nyl-2H-tetrazolium bromide (MTT) assay was performed
to evaluate mitochondrial function as a viability index of
SNAP-treated cells. No significant difference in cell vi-
ability was detected among cells treated with different
concentrations of SNAP (ranging from 25 to 1000 M)
(percentage of viability SNAP 1000 M, 92.34%; control
90.12%); in contrast, a nearly 2 log difference in HSV-2
production could be seen among infected cells treated
with different amounts of SNAP (Fig. 1A). These in vitro
results strongly suggest that NO decreased HSV-2, strain
G, replication either directly or indirectly without affect-
ing cell viability.
iNOS activation in vaginal tissues and inguinal lymph
nodes obtained from infected mice
To determine whether HSV-2 vaginal infection induced
iNOS expression, reverse transcriptase (RT)-PCR analysis
of vaginas, inguinal lymph nodes, or cells recovered from
vaginal washings of infected mice were performed at dif-
ferent days p.i. As shown in Fig. 2, HSV-2 infection in-
duced iNOS mRNA production in vagina, inguinal lymph
nodes, and cells obtained from vaginal washings of infected
animals from Day 1 p.i.
Effect of aminoguanidine (AG) on HSV-2 replication
in vivo
To investigate the effect of iNOS inhibition on HSV-2
vaginal infection, mice were treated intraperitoneally
from Day 2 to Day 4, considering Day 0 the day of
infection, with different amounts of AG. Virus was con-
sistently isolated from vaginal washings during the first
days after inoculation. As shown in Fig. 3A, virus titers
in vaginal washings obtained from AG-treated mice were
significantly higher than in control infected mice. Virus
clearence was also delayed in these animals. The effect
was dose-dependent, obtaining no significant modifica-
tion in viral replication when the lowest AG dose was
used. In the same way, virus titers obtained from vagi-
nal tissues were higher in treated animals, as shown in
Fig. 3B.
HSV-induced pathology in animals treated with iNOS
inhibitor
As observed in Fig. 4A, clinical scores were higher in
treated groups because of an augment in the pathology of
the HSV-induced vaginitis. Treated animals showed
higher levels of swelling or ulceration compared to con-
trols. The group treated with the lowest amount of AG
(0.2 mg) showed no differences with respect to control
(data not shown). These results were further confirmed by
microscopic histopathologic examination of hematoxylin
and eosin-stained vaginal sections obtained by standard
procedures. As is shown in Fig. 5B and D, at Day 8 p.i.,
vaginas from treated mice showed a conspicuous infil-
trate consisting primarily of PMN, compared to non-
treated animals. Edema and dilated blood vessels were
also more important in vaginal tissues obtained from
treated animals. A higher magnification (400, Fig. 5C
and D), revealed hemorrhage with profuse erythrocyte
infiltration in the tissue. The increased inflammatory ex-
udate observed in vaginal tissue of treated mice was
accompanied with a rise in total cell counts obtained from
vaginal washings of treated animals compared to controls
(Fig. 6A) during the first days p.i. Particularly, an aug-
ment in the percent of PMN was recorded in these sam-
ples (Fig. 6B). In addition, AG-treated infected groups
showed earlier death counts compared to controls (Fig.
4B), although by Day 12 p.i. death scores were similar
for treated and untreated mice. Animals that received
only AG but were uninfected did not show any sign of
morbility or PMN infiltration to tissues. No mortality was
recorded in this group (data not shown).
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Chemokine expression in vaginal tissues and inguinal
lymph nodes of infected mice
To determine if the observed increment in PMN counts
in vaginal tissues in AG-treated animals was related to an
increase in chemokine production, we investigated the ex-
pression of MIP-2 and RANTES in vaginas and inguinal
lymph nodes of infected animals.
RT-PCR analysis of MIP-2 expression revealed that this
chemokine was expressed in tissues of infected animals, but
as shown in Fig. 7A, while controls showed diminished
MIP-2 expression by Day 7 p.i., positive samples were still
obtained in treated animals. In addition, while we were not
able to detect MIP-2 expression in samples obtained from
inguinal lymph nodes recovered from control infected mice,
positive samples were recorded in AG-treated mice from
Day 3 to Day 7 p.i. (data not shown).
Similarly, more positive samples were recorded for
Fig. 1. (A) Effect of NO on HSV replication in vitro. Vero cells were grown to confluence in 24-well plates and infected with HSV-2 before adding culture
medium containing different concentrations of SNAP. The plates were incubated for 2 days, and then cells were freeze-thawed three times to obtain virus.
Virus yield was determined by the PFU method. Data are means SD of three independent experiments. (B) Nitrite production by SNAP in culture medium.
Equal volumes of medium from 48-h cultures of HSV-2-infected Vero cells supplemented with different concentrations of SNAP were added to Griess
reagent and incubated at room temperature for 10 min. The absorbance at 570 nm was measured using a microplate reader. NO2 concentration was
determined using NaNO2 as a standard and double-distilled water as a blank. Background NO2 values of buffer or medium were determined in each case
and subtracted from the experimental values.
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RANTES expression in vaginas of AG-treated infected an-
imals compared to controls 24 h p.i. (Fig. 7B), although no
differences were observed in inguinal lymph nodes.
Finally, we were not able to detect chemokine expression
in ip AG-treated (8 mg), noninfected matched controls in
the studied tissues (data not shown).
Discussion
During the acute phase of murine vaginal herpes sim-
plex virus infection, virus replication occurs on Days 2 to
8 p.i. in the vaginal epithelium, neuronal cells of the
uterovaginal plexus, and the dorsal root ganglia and
eventually spreads to the CNS. High replication rates in
the above tissues are usually associated with elevated
number of deaths on Days 8 to 13 p.i. Depending on the
strain of HSV used, swelling and redness either disappear
without consequence or lead to a further phase of inflam-
mation with ulcerations and necrosis of the vulva and hair
loss around the vulvar region. Symptoms mostly disap-
pear within 2 weeks (Podlech et al., 1997). Innate and
acquired immune mechanisms play important roles in the
control and resolution of viral infections. With respect to
mediators involved in the innate immune response, dif-
ferent studies had demonstrated the antiviral capability of
nitric oxide in vivo. Animals infected with different vi-
ruses and treated with NO production inhibitors have
shown an increase in viral replication and disease (Akarid
et al., 1995; Bi and Reiss et al., 1995; Hiraoka et al.,
1996; Mikami et al., 1996). In particular, we have pre-
viously reported antiviral activities of NO in an ocular
model of HSV infection (Benencia and Courre`ges, 1999;
Benencia et al., 2001). In this work, we investigated the
role of NO in HSV-2 vaginal infection in the mouse
model. First, we have observed that the iNOS expression
was detected in vaginas, inguinal lymph nodes, or cells
recovered from vaginal washings of infected animals. We
have also shown that NO has antiviral activity in vitro
and in vivo against HSV-2, detecting considerably higher
amounts of virus in vaginas and vaginal washings when
the animals were treated with aminoguanidine, an iNOS
inhibitor. An earlier appearance together with an aggra-
vation of the symptoms associated with the illness such
as inflammation, hair loss, and ulceration were observed
when NO production was impaired. Histopathology stud-
ies showed an increase in PMN infiltration to vaginal
tissues of AG-treated infected animals at Day 8 p.i.,
which could correlate with the higher MIP-2 expression
observed in the same tissues at Day 7 p.i. High levels of
disease were observed even on Day 28, while control
animals were nearly recovered. Moreover, mortality was
recorded earlier in AG-treated groups. These data indi-
cate a role of NO in the natural resistance against vaginal
infections with HSV and in the concomitant vaginal pa-
thology associated with the infection. With respect to this
issue, NO abrogation seemed to correlate with an in-
crease of PMN influx to vaginal tissues. The observed
effect may have at least two complementary causes. First,
it has been reported that productive infection with HSV
resulted in rapid up-regulation and sustained expression
of chemokines such as N51/KC, macrophage inflamma-
tory protein-1 (MIP-1), MIP-2, monocyte chemotactic
protein-1 (MCP-1), or cytokines such as IL-1, IL-6, IL-8,
IL-12, and TNF- (Su et al., 1996; Dahesia et al., 1998;
Thomas et al., 1998). In particular, IL-8 has been pointed
out as an important chemokine during HSV infection
(Oakes et al., 1993). Thus, an increase in viral titers
together with a delayed in viral clearance from vaginal
tissues caused by AG treatment could give rise to an
increase in chemokine expression, attracting more PMN
to the infected zone. Second, it has also been reported
that peroxynitrite, formed by the reaction between nitric
oxide and superoxide, regulates cytokine function during
inflammation. Peroxynitrite attenuates neutrophil and
monocyte chemotaxis induced by MIP-1 and IL-8 in a
dose-dependent manner possibly by inhibition of chemo-
kine binding to neutrophils and monocytes (Sato et al.,
2000a, 2000b). Thus, we hypothesize that the observed
increase in the influx of PMN to vaginas of treated mice
could also be due to the inhibition of NO production by
AG treatment during HSV infection, thus suppressing the
Fig. 2. iNOS mRNA expression in vaginas, inguinal lymph nodes, or cells
recovered from vaginal washings after HSV-2 infection. Tissues were
excised at the indicated times postinfection, after which 4 g of the
extracted total RNA was reverse transcribed. PCR was then carried out for
iNOS and -actin. The experiment was repeated three times with similar
results.
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NO-inhibitory effect over PMN chemotaxis (Sato et al.,
2000a, 2000b).
Finally, while we observed that inhibition of iNOS
during the first days of infection increased HSV infec-
tion, according to Fuji et al. (1999), intraperitoneal treat-
ment of rats with L-NMMA from Day 3 to Day 7 after
Fig. 3. Effect of AG treatment on viral concentration in vaginal washings (A) or vaginas (B) of mice inoculated intravaginally with HSV-2. Groups of five
female Balb/c mice, 4–6 weeks old, were subcutaneously inoculated with 2 mg of Depo-Provera per animal. Five days later vaginas were swabbed with a
cotton pledget soaked in PBS before inoculation 20 l of a viral suspension containing 5  105 PFU of HSV-2, strain G. The animals received a daily dose
(200 l) of AG (8 mg, ; 2 mg, Œ; and 0.4 mg, F) in PBS. This solution was intraperitoneally applied for 7 days, starting 2 days before infection. For 5
days postinfection (A) vaginal washings with 40 l of PBS were performed or (B) vaginal tissues were excised and homogenized in PBS. Obtained
suspensions were centrifuged to separate cells (A) or cell debris (B), and supernatants were titrated in Vero cell monolayers by using the PFU method. Data
are expressed as means  SD. The experiment was repeated three times with similar results. *P  0.05 respect to the control (E) group.
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intranasal HSV-1 infection decreased neurologic symp-
toms and increased survival of treated animals. They also
demonstrated that NO production is related with his-
topathologic changes in the brain during infection. Thus,
although NO production can be beneficial as an antiviral
effector mechanism against HSV-1 and other viruses, it
also may be detrimental by contributing to pathology
during immune responses as previously reported (Choi,
1993; Ruuls et al., 1996). To unravel the role of NO in
the natural resistance to HSV infections, it may be crucial
Fig. 4. (A) Effect of AG treatment on the clinical course of vaginal infection in Balb/c mice inoculated with HSV-2. Groups of 10 female Balb/c mice were
infected and treated as described in the legend to Fig. 3. Illness was scored as followed: no signs  0; slight inflammation  1; gross inflammation  2;
gross inflammation and hair loss  3; and gross inflammation, hair loss, and ulceration  4. Animal scores were averaged in each group to obtain a single
representative value. The experiment was repeated three times with similar results. (B) Effect of AG treatment on the mortality of Balb/c mice intravaginally
inoculated with HSV-2. Groups of 10 female Balb/c mice were infected and treated as described in the legend to Fig. 3. Mortality rates were recorded daily
for 2 weeks. The experiment was repeated three times with similar results. () 8 mg AG; (Œ) 4 mg AG; (E) control.
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to determine in which stage of viral disease this molecule
is exerting its major effect.
Materials and methods
Virus preparation
HSV-2, strain G, was used for all experiments. Virus
stocks were prepared in Vero cells and stored at 70°C.
Plaque-forming units (PFU) assays or virus titration were
performed on Vero cells as previously described (Benencia
et al., 2001). Viral stocks were adjusted at 107 PFU/ml.
Assay of NO antiviral activity in vitro
Vero cells were grown in 24-well plates. At confluence,
each well contained about 5  105 cells. Cell cultures were
infected with HSV-2 (multiplicity of infection 0.1 PFU/
cell), and virus was allowed to adsorb for 1 h at 37°C. Cell
monolayers were then washed three times with in minimum
essential medium (MEM, Life Technologies, Grand Island,
NY) to remove unadsorbed virus, and cell cultures were
incubated with MEM containing different concentrations
(25, 50, 250, and 1000 M) of SNAP (Calbiochem Corp.,
La Jolla, CA), a NO donor. The plates were incubated for 2
days at 37°C. At that time cells were freeze-thawed three
times, and after centrifugation supernatants were stored at




tetrazolium bromide, (Sigma Chemical Co., St. Louis, MO)
assay was used to measure mitochondrial function, which
served as an index of living cells. The MTT assay was
carried out as previously described (Sudo et al., 1994) with
minor modifications. Briefly, MTT was dissolved in 0.1 M
Tris-buffered saline to make a 5 mg/ml solution, which was
Fig. 5. Photomicrographs of vaginal tissue. Vaginas were removed from control and treated animals on Day 8 after infection. Vaginas from saline-treated
(A, C) and AG-treated (8-mg group) (B, D) mice are shown. Hematoxylin and eosin stain. Original magnification, A and B 100; C and D 400. The
experiment was repeated three times with similar results.
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then filtered to remove any insoluble residues. A 10-l
volume of MTT was added to each well containing test cells
with 100 l culture medium in a 96-well microtiter plate,
and the plate was incubated at 37°C for 4 h. At the end of
the incubation, the MTT solution was removed, and 200 l
of ethanol was added to dissolve the dark blue crystals
precipitated in the wells. A 100-l volume of the resulting
solution from each well was removed and read at 570 nm on
a microplate reader.
Nitrite determinations
Nitrite concentration in the medium, a measure of NO
production, was determined by a microplate assay using
Griess reagent (1% sulfanilamide, 0.1% naphthylethyl-
enediamine dihydrochloride, 2.5% phosphoric acid; Sigma
Chemical Co.) as previously described (Ding et al., 1988).
Inoculation of Balb/c mice
Female Balb/c mice, 4–10 weeks old, were used for all
experiments. Mice were treated with Depo-Provera (Sigma
Chemical Co.) (2 mg/mice) 5 days before vaginal infection
(Milligan and Bernstein, 1997). Animals were anesthetized
by intraperitoneal injection of 2 mg ketamine hydrochloride
(Ketalar, Parke Davis) and 0.04 mg xylazine (Rompun,
Mosby) in 0.1 ml of PBS. Then vaginas were swabbed with
a cotton pledget and then animals were inoculated intravag-
inally with 20 l of virus suspension (5  105 PFU). The
day of infection was considered as Day 0.
AG treatment of mice
Mice were separated in four experimental groups. Be-
tween Days 2 and 4 each mouse was inoculated intra-
peritoneally with 0.2 ml of different aminoguanidine
hemisulfate (Sigma Chemical Co.) solutions containing 8,
2, 0.4, or 0 mg (control) of the salt. An additional control
group received 8 mg of AG but remained uninfected. All
dilutions were prepared in PBS.
Fig. 7. (A) MIP-2 mRNA expression in vaginas after HSV-2 infection. (B)
RANTES mRNA expression in vaginas and inguinal lymph nodes after
HSV-2 infection. Tissues from control and 8-mg AG-treated mice were
excised at 24 h (RANTES) or 5 and 7 days (MIP-2) postinfection, after
which 4 g of the extracted total RNA was reverse transcribed. PCR was
then carried out for -actin, MIP-2 (A), or RANTES (B). The experiment
was repeated three times with similar results.
Fig. 6. (A) Viable cell counts of vaginal washing cells obtained from
control () and AG-treated () mice (8 mg). Groups of 10 female Balb/c
mice were infected and treated as described in the legend to Fig. 3. Viable
cell counts were obtained by trypan blue exclusion. (B) Composition of
vaginal washing cells obtained from control and AG-treated mice (8 mg).
Groups of 10 female Balb/c mice were infected and treated as described in
the legend to Fig. 3. The percentages of neutrophils ( ) monocytes (),
and lymphocytes () were determined by differential staining with May–
Grunwald–Giemsa. The experiment was repeated three times with similar
results. Data are expressed as means  SD. *P  0.05 with respect to the
control group.
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Viral replication and pathology in the reproductive tract
Following intravaginal HSV inoculation, mice were sam-
pled for 5 days by pipetting 40 l of PBS in and out of the
vagina. Vaginal washings were pooled and centrifuged at
1500 rpm for 10 min. Supernatants were used for viral
determinations, and a cell-containing pellet was used for
determining total cell counts by the trypan blue exclusion
method, with differential cell counting in smears stained by
May–Grunwald–Giemsa or for RT-PCR assays. These cells
consisted of a mixed population primarily composed by
PMNs, monocytes, and lymphocytes as previously de-
scribed (Milligan, 1999).
Groups of five mice were euthanized on Days 1 to 8
postinfection (p.i.) to obtain tissue samples of vagina. Tis-
sues were excised and collected into 1 ml MEM, minced
with scissors, and homogenized using an electric blender.
Samples were sonicated in an ice-cold water bath for 1 min
and centrifuged 3000 rpm for 10 min. Virus in supernatants
was evaluated by the PFU assay.
Genital pathology and mortality were monitored daily
for 4 weeks following HSV infection and scoring was per-
formed blinded. Illness was scored as followed: no signs 
0; slight inflammation  1; gross inflammation  2; gross
inflammation and hair loss  3; gross inflammation, hair
loss, and ulceration  4 (Galichan and Rosenthal, 1996).
Animal scores were averaged in each group to obtain a
single representative value. Groups initially consist of 10
animals each.
Evaluation of histopathologic lesions
Vaginas of treated and control mice were removed at
different days p.i. and placed in 10% buffered neutral for-
malin, embedded in paraffin, stained with hematoxylin and
eosin, mounted with Permount, and covered with a cover-
slip for microscopic examination. Five representative sec-
tions of each vagina were examined to evaluate histopathol-
ogy and inflammatory infiltrate characteristics.
Reverse transcription–PCR analysis
iNOS, RANTES, and MIP-2 expression in vaginas, in-
guinal lymph nodes, or cells recovered from vaginal wash-
ings of infected animals was investigated. For iNOS studies,
groups of five mice were euthanized from Days 1 to 8 p.i.,
samples were collected and pooled, and RNA was extracted
with RNAgents total isolation system (Promega Corp.,
Madison, WI) according to the manufacturer’s instructions.
For RANTES and MIP-2 expression studies, groups of four
mice were used, and individual RNA was studied. After
DNase treatment, first-strand cDNA was synthesized from 4
g of RNA using an oligo (dT15) primer and M-MLV RT
(Promega Corp.) in a 40-l reaction volume. PCR on cDNA
was performed using the following pairs of primers: iNOS
(sense, 5-CTT CCG AAG TTT CTG GCA GCA GCG-3;
antisense, 5-GAG CCT GCT GGC TTT GGG CTC CTC-
3); MIP-2 (sense, 5-AGT TTG CCT TGA CCC TGA
AGC C-3; antisense, 5-TGG GTG GGA TGT AGC TAG
TTC C-3); and RANTES (sense, 5-GAA GAT CTC TGC
AGC TGC CCT-3; antisense, 5-GCT CAT CTC CAA
ATA GTT GA-3) that generated 487-, 445-, and 300-bp
products, respectively.
Expression of -actin mRNA in the same samples was
used as a control for RNA isolation. The first cycle of PCR
was at 95°C for 5 min, 52°C for 1 min, and 72°C for 1 min
followed by 45 (iNOS, MIP-2, or RANTES) or 32 (-actin)
cycles of 94°C (1 min), decreasing to 52°C (1 min), and
increasing to 72°C (1 min). PCR products were resolved in
1.5% agarose gels and visualized by ethidium bromide
staining.
Statistical analysis
The data were analyzed by using the Student t test for the
in vitro experiments and the 2 method for the in vivo
experiments.
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